

=====

Sequence Listing was accepted with existing errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Tue Jun 05 18:26:55 EDT 2007

=====

Application No: 10594507

Version No: 1.1

Input Set:

Output Set:

Started: 2007-06-05 18:26:48.239

Finished: 2007-06-05 18:26:49.058

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 819 ms

Total Warnings: 14

Total Errors: 0

No. of SeqIDs Defined: 15

Actual SeqID Count: 15

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)

# SEQUENCE LISTING

<110> Sugiyama, Haruo

<120> Cancer antigen peptides derived from WT1

<130> 296846US0PCT

<140> 10/594,507

<141> 2006-09-28

<150> PCT/JP05/06113

<151> 2005-03-30

<150> JP 2004-105219

<151> 2004-03-31

<160> 15

<170> PatentIn version 3.3

<210> 1

<211> 449

<212> PRT

<213> Homosapiens

<400> 1

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro  
1 5 10 15

Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala  
20 25 30

Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr  
35 40 45

Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro Pro  
50 55 60

Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly  
65 70 75 80

Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe  
85 90 95

Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe  
100 105 110

Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe

115

120

125

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile  
 130 135 140

Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr  
 145 150 155 160

Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe  
 165 170 175

Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln  
 180 185 190

Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser  
 195 200 205

Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp  
 210 215 220

Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln  
 225 230 235 240

Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser  
 245 250 255

Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu  
 260 265 270

Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile  
 275 280 285

His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro  
 290 295 300

Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys  
 305 310 315 320

Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys  
 325 330 335

Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro  
 340 345 350

Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp  
355 360 365

Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln  
370 375 380

Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr  
385 390 395 400

His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys  
405 410 415

Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val  
420 425 430

Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala  
435 440 445

Leu

<210> 2  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 2

Asp Gln Leu Lys Arg His Gln Arg Arg  
1 5

<210> 3  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 3

Asp Leu Asn Ala Leu Leu Pro Ala Val  
1 5

<210> 4  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa is Leu, Met, Val, Ile, or Gln

<220>  
<221> MISC\_FEATURE  
<222> (9)..(9)  
<223> Xaa is Val or Leu

<400> 4

Asp Xaa Asn Ala Leu Leu Pro Ala Xaa  
1 5

<210> 5  
<211> 16  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 5

Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His  
1 5 10 15

<210> 6  
<211> 21  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 6

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser  
1 5 10 15

Ala Ser His Leu Glu  
20

<210> 7  
<211> 16  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 7

Ala Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu  
1 5 10 15

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 8

Val Thr Phe Asp Gly Thr Pro Ser Tyr  
1 5

<210> 9  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 9

Gln Gly Ser Leu Gly Glu Gln Gln Tyr  
1 5

<210> 10  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 10

Phe Ala Pro Pro Gly Ala Ser Ala Tyr  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 11

Pro Ile Leu Cys Gly Ala Gln Tyr Arg  
1 5

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 12

Gly Val Phe Arg Gly Ile Gln Asp Val Arg  
1 5 10

<210> 13  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 13

Cys Leu Glu Ser Gln Pro Ala Ile Arg  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 14

Lys Arg Tyr Phe Lys Leu Ser His Leu  
1 5

<210> 15

<211> 9  
<212> PRT  
<213> Artificial

<220>  
<223> Synthetic peptide

<400> 15

Ala Leu Leu Pro Ala Val Pro Ser Leu  
1 5